Related Experiment Videos
[Antiangiogenic therapy for pterygium recurrence]
S Leippi1, F Grehn, G Geerling
1Klinik für Augenheilkunde, Universitätsaugenklinik, Josef-Schneider-Strasse 11, 97080, Würzburg.
Summary
Topical Bevacizumab eye drops show promise in preventing pterygium recurrence after surgery. This anti-vascular endothelial growth factor (VEGF) treatment may reduce the need for repeat procedures in patients with recurrent pterygia.
Area of Science:
- Ophthalmology
- Vascular Biology
Background:
- Pterygium is a degenerative limbal tissue growth.
- Vascular endothelial growth factor (VEGF) is implicated in pterygium development.
- Surgical recurrence is a significant postoperative challenge.
Purpose of the Study:
- To evaluate the efficacy of Bevacizumab eye drops in preventing recurrent pterygia.
- To assess the anti-VEGF effect of Bevacizumab as an adjunct therapy post-pterygium excision.
Main Methods:
- Topical Bevacizumab (25 mg/ml) was administered 2-8 times daily for 5-24 weeks post-surgery.
- Treatment was applied as an adjunct to pterygium excision and conjunctival autograft.
- Follow-up ranged from 3-14 months (median 12 months).
Main Results:
- Visual acuity improved in 3 of 5 eyes.
- One eye showed no recurrence; others had mild to moderate recurrence (hyperemia, fibrosis, corneal vascularization).
- No serious permanent complications were observed.
Conclusions:
- Topical Bevacizumab demonstrates potential in managing recurrent pterygia.
- Mid-term follow-up supports the use of topical VEGF inhibitors for recurrent pterygia.
- Further research is warranted to confirm efficacy and safety.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...